



## Sustained abdominal discomfort in a 57-year-old woman

Hisayo Nishiura, Hiroshi Nakase and Tsutomu Chiba

*Gut* 2010 59: 578

doi: 10.1136/gut.2009.189647

---

Updated information and services can be found at:

<http://gut.bmj.com/content/59/5/578.full.html>

---

*These include:*

**Email alerting  
service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

**Notes**

---

To order reprints of this article go to:

<http://gut.bmj.com/cgi/reprintform>

To subscribe to *Gut* go to:

<http://gut.bmj.com/subscriptions>

11. **Gisbert JP**, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after *Helicobacter pylori* treatment failure. *Aliment Pharmacol Ther* 2006;**23**:35–44.
12. **Saad RJ**, Schoenfeld P, Kim HM, *et al*. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent *Helicobacter pylori* infection: a meta-analysis. *Am J Gastroenterol* 2006;**101**:488–96.
13. **Gisbert JP**, Bermejo F, Castro-Fernández M, *et al*. Second-line rescue therapy with levofloxacin after *H. pylori* treatment failure: a Spanish multicenter study of 300 patients. *Am J Gastroenterol* 2008;**103**:71–6.
14. **Rokkas T**, Sechopoulos P, Robotis I, *et al*. Cumulative *H. pylori* eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. *Am J Gastroenterol* 2009;**104**:21–5.
15. **Lee YC**, Wu HM, Chen TH, *et al*. A community-based study of *Helicobacter pylori* therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. *Helicobacter* 2006;**11**:418–24.
16. **Zullo A**, Perna F, Hassan C, *et al*. Primary antibiotic resistance in *Helicobacter pylori* strains isolated in northern and central Italy. *Aliment Pharmacol Ther* 2007;**25**:1429–34.
17. **Hung KH**, Sheu BS, Chang WL, *et al*. Prevalence of primary fluoroquinolone resistance among clinical isolates of *Helicobacter pylori* at a University Hospital in Southern Taiwan. *Helicobacter* 2009;**14**:61–5.
18. **Calvet X**, García N, López T, *et al*. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2000;**14**:603–9.
19. **Dunbar LM**, Wunderink RG, Habib MP, *et al*. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. *Clin Infect Dis* 2003;**37**:752–60.
20. **Shorr AF**, Khashab MM, Xiang JX, *et al*. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. *Respir Med* 2006;**100**:2129–36.
21. **Hadley JA**. Value of short-course antimicrobial therapy in acute bacterial rhinosinusitis. *Int J Antimicrob Agents* 2005;**26** Suppl 3:S164–9.
22. **Gisbert JP**. 'Rescue' regimens after *Helicobacter pylori* treatment failure. *World J Gastroenterol* 2008;**14**:5385–402.
23. **Chen TS**, Chang FY, Chen PC, *et al*. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 2003;**18**:1237–43.
24. **Koletzko S**, Richey F, Bontems P, *et al*. Prospective multicentre study on antibiotic resistance of *Helicobacter pylori* strains obtained from children living in Europe. *Gut* 2006;**55**:1711–16.
25. **Rispo A**, Di Girolamo E, Cozzolino A, *et al*. Levofloxacin in first-line treatment of *Helicobacter pylori* infection. *Helicobacter* 2007;**12**:364–5.
26. **Antos D**, Schneider-Brachert W, Bästlein E, *et al*. 7-day triple therapy of *Helicobacter pylori* infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. *Helicobacter* 2006;**11**:39–45.
27. **Liou JM**, Chen CY, Wu MS, *et al*. Comparative study of modified-release clarithromycin and immediate-release clarithromycin in the treatment of *Helicobacter pylori*-associated peptic ulcer disease. *Hepatogastroenterology* 2006;**53**:784–8.
28. **Cheng HC**, Chang WL, Chen WY, *et al*. Levofloxacin-containing triple therapy to eradicate the persistent *H. pylori* after a failed conventional triple therapy. *Helicobacter* 2007;**12**:359–63.
29. **Gasbarrini A**, Ojetti V, Armuzzi A, *et al*. Efficacy of a multistep strategy for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2000;**14**:79–83.
30. **Chan FK**, Sung JJ, Suen R, *et al*. Salvage therapies after failure of *Helicobacter pylori* eradication with ranitidine bismuth citrate-based therapies. *Aliment Pharmacol Ther* 2000;**14**:91–5.
31. **Gomollón F**, Valdepérez J, Garuz R, *et al*. Cost-effectiveness analysis of 2 strategies of *Helicobacter pylori* eradication: results of a prospective and randomized study in primary care. *Med Clin (Barc)* 2000;**115**:1–6.
32. **Zervos MJ**, Hershberger E, Nicolau DP, *et al*. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. *Clin Infect Dis* 2003;**37**:1643–8.
33. **Carothers JJ**, Bruce MG, Hennessy TW, *et al*. The relationship between previous fluoroquinolone use and levofloxacin resistance in *Helicobacter pylori* infection. *Clin Infect Dis* 2007;**44**:e5–8.
34. **Sheng WH**, Chen YC, Wang JT, *et al*. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. *Diagn Microbiol Infect Dis* 2002;**43**:141–7.
35. **Nikaido H**. Antibiotic resistance caused by gram-negative multidrug efflux pumps. *Clin Infect Dis* 1998;**27** Suppl 1:S32–41.
36. **Liu ZQ**, Zheng PY, Yang PC. Efflux pump gene *hefA* of *Helicobacter pylori* plays an important role in multidrug resistance. *World J Gastroenterol* 2008;**14**:5217–22.
37. **Cambau E**, Allerheiligen V, Coulon C. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in *Helicobacter pylori*. *J Clin Microbiol* 2009;**47**:3600–7.

## Editor's quiz: GI snapshot

### Sustained abdominal discomfort in a 57-year-old woman

#### CLINICAL PRESENTATION

A 57-year-old woman presented with lower abdominal discomfort. Chinese herbs had been administered for 8 years. Physical examination revealed no abdominal findings. Laboratory data revealed a mild increase of C reactive protein (0.8 mg/dl) alone. Occult blood in stool was positive. Barium enema examination demonstrated a thumb-printing sign, sclerosis of the colonic wall and luminal narrowing of the ascending and the transverse colon. Abdominal CT scan without contrast media revealed wall thickening of ascending and transverse colon with markedly linear and nodular calcification along colonic wall and mesocolic blood vessels (figure 1).



**Figure 1** Abdominal CT scan without contrast media showing thickened colonic wall of both ascending and transverse colon with markedly linear and nodular calcification along colonic wall and mesocolic blood vessels.

#### QUESTION

What is the diagnosis?

See page 594 for the answer

#### Hisayo Nishiura, Hiroshi Nakase, Tsutomu Chiba

Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

**Correspondence to** Dr Hiroshi Nakase, Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University,

54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; [hiropy\\_n@kuhp.kyoto-u.ac.jp](mailto:hiropy_n@kuhp.kyoto-u.ac.jp)

**Contributors** Hisayo Nishiura and Hiroshi Nakase drafted the article. Hiroshi Nakase also offered critical revision of the article for important intellectual content, and gave final approval of the article. Tsutomu Chiba gave final approval of the article.

**Ethics approval** This study was conducted with the approval of the Institutional Review Board of Kyoto University.

**Patient consent** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

*Gut* 2010;**59**:578. doi:10.1136/gut.2009.189647



## Editor's quiz: GI snapshot

BMJ Publishing Group Ltd and British Society of Gastroenterology

*Gut* 2010 59: 594

doi: 10.1136/gut.2009.189647a

---

Updated information and services can be found at:

<http://gut.bmj.com/content/59/5/594.full.html>

---

*These include:*

### References

This article cites 3 articles

<http://gut.bmj.com/content/59/5/594.full.html#ref-list-1>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Notes

---

To order reprints of this article go to:

<http://gut.bmj.com/cgi/reprintform>


To subscribe to *Gut* go to:

<http://gut.bmj.com/subscriptions>

**ANSWER**

From the question on page 578

The diagnosis is idiopathic mesenteric phlebosclerosis (IMP). Colonoscopic examination demonstrated oedematous and dark purple mucosa with erosion (figure 1). The most severe lesions were located from the caecum to the transverse colon. Histological examination of a biopsy specimen revealed deep mucosal perivascular fibrosis and vascular wall sclerosis with mild mucosal inflammation. Congo red and diron staining was not positive. These findings suggested that the patient was diagnosed with IMP, which is a rare disease characterised by mesenteric venous calcification and colonic wall thickening with fibrosis.<sup>1</sup> IMP mainly involves the right colon in a continuous distribution and sometimes, the distal colon, and terminal ileum. In 2003, Iwashita *et al* proposed IMP as a new disease entity causing ischaemic colitis.<sup>2</sup> The pathogenesis of IMP has not been established and the cause is still unclear. It is speculated that long-standing and direct hypoxic injury to the venous muscular layer by any causes (toxic agents) might elicit gradual mummification and then sclerosis and calcification. Portal hypertension, diabetes mellitus, hyperlipidaemia, and autoimmune disease, and long-term administration of Chinese herbs (as in our case) have been considered as causes of IMP.<sup>3</sup> Prognosis of IMP is benign; however, surgical treatment might be required when patients with IMP complain of exacerbating abdominal obstructive symptoms.



**Figure 1** Colonoscopic view showing oedematous and dark purple mucosa with erosion.

*Gut* 2010;**59**:594. doi:10.1136/gut.2009.189647a

**REFERENCES**

1. **Arimura Y**, Kondoh Y, Kurokawa S, *et al*. Chronic ischemic colonic lesion caused by phlebosclerosis with calcification. *Am J Gastroenterol* 1998;**93**:2290–2.
2. **Iwashita A**, Yao T, Schemper RJ, *et al*. Mesenteric phlebosclerosis: a new disease entity causing ischemic colitis. *Dis Colon Rectum* 2003;**46**:209–20.
3. **Chang KM**. New histologic findings in idiopathic mesenteric phlebosclerosis: clues to its pathogenesis and etiology-probably ingested toxic agent-related. *J Clin Med Assoc* 2007;**70**:227–35.